<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362905</url>
  </required_header>
  <id_info>
    <org_study_id>Lidocaine in IUD pain</org_study_id>
    <nct_id>NCT03362905</nct_id>
  </id_info>
  <brief_title>Lidocaine for Pain Control During Intrauterine Device Insertion</brief_title>
  <official_title>Lidocaine for Pain Control During Intrauterine Device Insertion: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite being the most common method of contraception, the use of intrauterine devices (IUDs)
      is limited by the associated pain during insertion. Many pharmacologic interventions had been
      studied for their efficacy to reduce IUD insertion pain, of them, lidocaine was found to be
      superior over NSAIDs or other local anesthetics. This work aims at comparing the safety and
      efficacy of different lidocaine formulations to optimize selection in reduction of IUD
      associated pain.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 3, 2017</start_date>
  <completion_date type="Anticipated">January 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will include 123 patients who are candidates for IUD contraception. The aim of the study will be explained to all patients and an informed written consent will be taken. After recruitment, patients will be randomized to the 3 study arms using computer generated randomization sheet using MedCalcc version 13 to receive any of: lidocaine spray, cream and injection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores assessed by 10-point VAS scale</measure>
    <time_frame>1 year</time_frame>
    <description>VAS scores will be assessed on at three different points; baseline after application of speculum and analgesic administration, after grasping cervix with tenaculum, then following hysterometry and IUD insertion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction to IUD insertion</measure>
    <time_frame>1 year</time_frame>
    <description>Satisfaction will be assessed post-procedure using patient directed survey</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>IUD Insertion Complication</condition>
  <arm_group>
    <arm_group_label>Lidocaine spray Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine cream Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine injection Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine topical</intervention_name>
    <description>Local anesthetic for reduction of IUD associated pain</description>
    <arm_group_label>Lidocaine spray Arm</arm_group_label>
    <arm_group_label>Lidocaine cream Arm</arm_group_label>
    <arm_group_label>Lidocaine injection Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Multiparous women.

          2. Over 18 years of age and eligible for IUD insertion.

          3. Application of IUD will be done in postmenstrual period.

        Exclusion Criteria:

        Null parity. 2. History of failed intrauterine device insertion (uterine perforation, acute
        expulsion).

        3. Copper allergy. 4. Uterine anomaly. 5. Post-partum endometritis or septic abortion in
        the past three months. 6. Untreated cervicitis/vaginitis, including bacterial vaginosis. 7.
        Immunosuppression. 8. History of lidocaine ,prilocaine allergy. 9. Analgesic or anxiolytic
        use within the last 24 hours before the procedure. 10. Wilson's disease. 11. Suspicion of
        pregnancy. 12. Untreated abnormal uterine bleeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hadeer Elhagri, M.B.B.Ch</last_name>
    <phone>01098357256</phone>
    <email>hadeer.elhagri@med.asu.edu.eg</email>
  </overall_contact>
  <reference>
    <citation>Aksoy H, Aksoy Ü, Ozyurt S, Açmaz G, Babayigit M. Lidocaine 10% spray to the cervix reduces pain during intrauterine device insertion: a double-blind randomised controlled trial. J Fam Plann Reprod Health Care. 2016 Apr;42(2):83-7. doi: 10.1136/jfprhc-2014-100917. Epub 2015 Mar 10.</citation>
    <PMID>25759418</PMID>
  </reference>
  <reference>
    <citation>Buhling KJ, Hauck B, Dermout S, Ardaens K, Marions L. Understanding the barriers and myths limiting the use of intrauterine contraception in nulliparous women: results of a survey of European/Canadian healthcare providers. Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:146-54. doi: 10.1016/j.ejogrb.2014.10.020. Epub 2014 Oct 30.</citation>
    <PMID>25461369</PMID>
  </reference>
  <reference>
    <citation>Lopez LM, Bernholc A, Zeng Y, Allen RH, Bartz D, O'Brien PA, Hubacher D. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev. 2015 Jul 29;(7):CD007373. doi: 10.1002/14651858.CD007373.pub3. Review.</citation>
    <PMID>26222246</PMID>
  </reference>
  <reference>
    <citation>Gemzell-Danielsson K, Mansour D, Fiala C, Kaunitz AM, Bahamondes L. Management of pain associated with the insertion of intrauterine contraceptives. Hum Reprod Update. 2013 Jul-Aug;19(4):419-27. doi: 10.1093/humupd/dmt022. Epub 2013 May 12. Review.</citation>
    <PMID>23670222</PMID>
  </reference>
  <reference>
    <citation>Bahamondes L, Mansour D, Fiala C, Kaunitz AM, Gemzell-Danielsson K. Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives. J Fam Plann Reprod Health Care. 2014 Jan;40(1):54-60. doi: 10.1136/jfprhc-2013-100636. Epub 2013 Sep 27. Review.</citation>
    <PMID>24076534</PMID>
  </reference>
  <reference>
    <citation>Akers AY, Steinway C, Sonalkar S, Perriera LK, Schreiber C, Harding J, Garcia-Espana JF. Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. Obstet Gynecol. 2017 Oct;130(4):795-802. doi: 10.1097/AOG.0000000000002242.</citation>
    <PMID>28885425</PMID>
  </reference>
  <reference>
    <citation>Tavakolian S, Doulabi MA, Baghban AA, Mortazavi A, Ghorbani M. Lidocaine-Prilocaine Cream as Analgesia for IUD Insertion: A Prospective, Randomized, Controlled, Triple Blinded Study. Glob J Health Sci. 2015 Jan 27;7(4):399-404. doi: 10.5539/gjhs.v7n4p399.</citation>
    <PMID>25946948</PMID>
  </reference>
  <reference>
    <citation>Golzari SE, Soleimanpour H, Mahmoodpoor A, Safari S, Ala A. Lidocaine and pain management in the emergency department: a review article. Anesth Pain Med. 2014 Feb 15;4(1):e15444. doi: 10.5812/aapm.15444. eCollection 2014 Feb. Review.</citation>
    <PMID>24660158</PMID>
  </reference>
  <reference>
    <citation>Mody SK, Kiley J, Rademaker A, Gawron L, Stika C, Hammond C. Pain control for intrauterine device insertion: a randomized trial of 1% lidocaine paracervical block. Contraception. 2012 Dec;86(6):704-9. doi: 10.1016/j.contraception.2012.06.004. Epub 2012 Jul 6.</citation>
    <PMID>22770792</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hadeer Abd-El Shafy Fouad</investigator_full_name>
    <investigator_title>Resident physician</investigator_title>
  </responsible_party>
  <keyword>Lidocaine</keyword>
  <keyword>Dosage forms</keyword>
  <keyword>Pain scores</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

